First Indication Milestones Sample Clauses
First Indication Milestones. In partial consideration of the rights and licenses granted by ICAgen to YAMANOUCHI under this Agreement, YAMANOUCHI shall pay ICAgen each of the following milestone payments upon the first occurrence of each event set forth below with respect to any Clinical Compound or Product based thereon that YAMANOUCHI elects to develop and commercialize pursuant to Section 2.12 and with which YAMANOUCHI, a YAMANOUCHI Affiliate or a YAMANOUCHI Sublicensee achieves such milestone; provided that each of the following milestone payments shall be payable only with respect to one Clinical Compound or Product based thereon:
(i) $[**] upon commencement of [**];
(ii) $[**] upon [**];
(iii) $[**] upon [**];
(iv) $[**] upon [**];
(v) $[**] upon [**];
(vi) $[**] upon [**];
(vii) $[**] upon [**]; and
(viii) $[**] upon [**].
First Indication Milestones. Each of the following amounts will be payable by MSD to NEUROGEN within thirty (30) days following the achievement of the event specified below with respect to any Product:
(A) Upon the first NDA Approval in the US - [ ]*;
(B) Upon the first NDA Approval in the EU if approval is sought via the centralized filing procedure [ ]*; or, if approved independently by countries in the EU, [ ]* for NDA Approval in each of the United Kingdom, France, Germany, Italy and Spain; and
(C) Upon the first NDA Approval in Japan - [ ]*.
First Indication Milestones. OBI shall make the non-refundable, non-creditable payments to Millennium set forth below not later than 20 Business Days after the earliest date on which the corresponding milestone event set forth below has been achieved:
(i) Earlier of enrollment of the [**] 612th patient in or completion of study enrollment pursuant to the applicable protocol for the Phase III Clinical Study of the Product in the First Indication ongoing as of the Effective Date ----------------------------------- ---------------------------------------- (ii) Regulatory Approval in the [**] first Major European Country or EMEA of the Product for the First Indication ----------------------------------- ----------------------------------------
First Indication Milestones. Upon the first achievement of the following milestone events by HGS, NVS, Affiliates or its Permitted Sublicensees under this Agreement for the First Indication only for the Collaboration Product arising hereunder, HGS shall invoice and NVS shall pay the following one-time milestone payments: Milestone Event First Indication
(a) [***] U.S. $[***] (b) [***] U.S. $[***] (c) [***] U.S. $[***] (d) [***] U.S. $[***] (e) [***] U.S. $[***] (f) [***] U.S. $[***] [***] U.S. $[***]